Literature DB >> 2848408

Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas.

R I Linnoila1, J L Mulshine, S M Steinberg, K Funa, M J Matthews, J D Cotelingam, A F Gazdar.   

Abstract

Bronchial carcinoids and small cell lung cancer (SCLC) are currently recognized as neuroendocrine (NE) neoplasms. However, non-SCLC (NSCLC) may also express NE properties. Paraffin-embedded sections of a comprehensive panel of 113 lung carcinomas were analyzed for the expression of three general markers common to all NE cells, namely, chromogranin A, Leu-7 and neuron-specific enolase (NSE), five specific NE secretory products, and four other tumor markers by immunohistochemistry using the sensitive avidin-biotinylated peroxidase technique. The authors were able to demonstrate the following: (1) most, but not all carcinoids and SCLCs expressed multiple NE markers in a high percentage of tumor cells; (2) up to a half of NSCLC cases contained small subpopulations of cells expressing NE in a high percentage of tumor cells; (2) up to half of NSCLC cases contained small subpopulations of cells expressing NE markers; and (3) occasional NSCLCs showed staining patterns indistinguishable from SCLC. Specifically, 7 of 77 NSCLCs expressed four or more NE markers. NE markers in NSCLCs were more commonly expressed in adenocarcinomas and large cell carcinomas and rarely in squamous cell carcinomas. For comparison, the mean number of NE markers expressed by all cases of NSCLC was 1.5, carcinoids 6.0, and SCLCs 3.8. Individual "marker counts" were not useful in categorizing lung tumors as carcinoids and SCLC versus NSCLC. Instead, 95% of the tumors were correctly classified, applying a statistical model created from staining indices of the three general NE markers (chromogranin A, Leu-7, NSE) and three other tumor markers (carcinoembryonic antigen, keratin, vimentin). Because NSCLCs with NE features might have different clinical characteristics than other NSCLCs, immunohistochemistry provides an effective manner to identify this biologically interesting subset of NSCLCs in routine paraffin sections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2848408     DOI: 10.1093/ajcp/90.6.641

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  31 in total

Review 1.  Extrapulmonary small cell carcinoma.

Authors:  J A Ledermann
Journal:  Postgrad Med J       Date:  1992-02       Impact factor: 2.401

Review 2.  Lung cancer.

Authors:  R Souhami
Journal:  BMJ       Date:  1992-05-16

Review 3.  New perspectives in lung cancer. 3. The antigens of lung cancer.

Authors:  R L Souhami
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

4.  Immunohistochemical demonstration of chromogranin A, chromogranin B, and secretoneurin in primary non-small-cell carcinomas of the lung.

Authors:  Martin Tötsch; Birgit Kunk; Barbara Dockhorn-Dworniczak; Dietmar Öfner; Reiner Fischer-Colbrie; Gregor Mikuz; Werner Böcker; Kurt Werner Schmid
Journal:  Endocr Pathol       Date:  1994-12       Impact factor: 3.943

5.  Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration.

Authors:  S D Reynolds; A Giangreco; J H Power; B R Stripp
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

6.  Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation.

Authors:  S X Jiang; T Kameya; Y Sato; N Yanase; H Yoshimura; T Kodama
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

7.  Loss of GFI1 impairs pulmonary neuroendorine cell proliferation, but the neuroendocrine phenotype has limited impact on post-naphthalene airway repair.

Authors:  R Ilona Linnoila; Sandra Jensen-Taubman; Avedis Kazanjian; H Leighton Grimes
Journal:  Lab Invest       Date:  2007-04       Impact factor: 5.662

8.  Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma.

Authors:  C M Kirsch; J von Pawel; I Grau; K Tatsch
Journal:  Eur J Nucl Med       Date:  1994-12

9.  Reliability of commercially available immunocytochemical markers for identification of neuroendocrine differentiation in bronchoscopic biopsies of bronchial carcinoma.

Authors:  J R Gosney; M A Gosney; M Lye; S A Butt
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

10.  Serum neuron-specific enolase and immunohistochemical markers of neuroendocrine differentiation in lung cancer.

Authors:  P O'Shea; M Cassidy; R Freaney; P McCarthy; J Fennelly
Journal:  Ir J Med Sci       Date:  1995-01       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.